Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Methods of Nuclear Reprogramming01:24

Methods of Nuclear Reprogramming

1.9K
Nuclear reprogramming is a process of transforming one cell type into an unrelated cell type by epigenetic changes that alter the cell’s original gene expression pattern. Such epigenetic changes force cells to express a different set of genes, which play a significant role in inducing transformation into other cell types. Nuclear reprogramming offers applications in reproductive cloning for livestock propagation and regenerative medicine — developing patient-specific cells for...
1.9K
Introduction to Nuclear Reprogramming01:14

Introduction to Nuclear Reprogramming

2.0K
Nuclear reprogramming is the process of switching gene expression of one cell type to that of another cell type, usually from a differentiated cell state to an undifferentiated cell state. Differentiation occurs during processes such as development and morphogenesis, tissue regeneration, and malignancy. Cells can also be artificially induced to reprogram their gene expression by techniques such as nuclear transfer, induced pluripotency, and cell fusion. Such techniques have many applications in...
2.0K
Lineage Commitment01:21

Lineage Commitment

3.1K
Commitment is the  process whereby stem cells:
3.1K
Somatic to iPS Cell Reprogramming01:29

Somatic to iPS Cell Reprogramming

2.3K
Reprogramming alters the gene expression in somatic cells, transforming them into induced pluripotent stem (iPS) cells over several generations. Scientists can reprogram cells by introducing genes for four transcription factors—Oct4, Sox2, Klf4, and c-Myc (OSKM) by viral or non-viral methods. These factors are also known as Yamanaka factors after Shinya Yamanaka, who first generated iPS cells using mouse skin cells. Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012...
2.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genome-Wide CRISPR/Cas9 Screening Identifies Modulators of THZ1 Response in Acute Myeloid Leukemia.

Biomedicines·2026
Same author

Targeting the nuclear export receptor exportin-1 in acute myeloid leukaemia: From biology to clinical translation.

Clinical and translational medicine·2026
Same author

Reconstitution of the Multiple Myeloma Microenvironment Following Lymphodepletion with BCMA CAR-T Therapy.

Clinical cancer research : an official journal of the American Association for Cancer Research·2024
Same author

Validation and modification of simplified Geriatric Assessment and Elderly Prognostic Index: Effective tools for older patients with diffuse large B-cell lymphoma.

Cancer medicine·2023
Same author

Nucleolar and spindle associated protein 1 enhances chemoresistance through DNA damage repair pathway in chronic lymphocytic leukemia by binding with RAD51.

Cell death & disease·2021
Same author

Prognostic and Therapeutic Value of Apolipoprotein A and a New Risk Scoring System Based on Apolipoprotein A and Adenosine Deaminase in Chronic Lymphocytic Leukemia.

Frontiers in oncology·2021

Related Experiment Video

Updated: Sep 6, 2025

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

21.4K

Targeting metabolic reprogramming in chronic lymphocytic leukemia.

Yu Nie1,2,3,4,5, Xiaoya Yun1,2,3,4,5, Ya Zhang6,7,8,9

  • 1Department of Hematology, Shandong Provincial Hospital, Shandong University, No. 324, Jingwu Road, Jinan, 250021, Shandong, China.

Experimental Hematology & Oncology
|June 27, 2022
PubMed
Summary

Metabolic reprogramming drives chronic lymphocytic leukemia (CLL) progression. Targeting cancer cell metabolism, including glycolysis and oxidative phosphorylation, offers promising therapeutic strategies for improving patient survival.

Keywords:
Chronic lymphocytic leukemiaLipid metabolismMetabolism reprogrammingTargeted therapy

More Related Videos

Assessment of the Metabolic Profile of Primary Leukemia Cells
06:21

Assessment of the Metabolic Profile of Primary Leukemia Cells

Published on: November 21, 2018

10.6K
Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking
11:39

Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking

Published on: October 23, 2019

11.6K

Related Experiment Videos

Last Updated: Sep 6, 2025

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

21.4K
Assessment of the Metabolic Profile of Primary Leukemia Cells
06:21

Assessment of the Metabolic Profile of Primary Leukemia Cells

Published on: November 21, 2018

10.6K
Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking
11:39

Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking

Published on: October 23, 2019

11.6K

Area of Science:

  • Oncology
  • Cancer Metabolism
  • Hematologic Malignancies

Background:

  • Metabolic reprogramming is crucial in cancer development and progression.
  • Abnormal metabolism in chronic lymphocytic leukemia (CLL) cells affects their proliferation and survival compared to normal B cells.
  • The specific role of metabolic reprogramming in CLL requires further investigation.

Purpose of the Study:

  • To review critical metabolic processes in CLL, including glycolysis, lipid metabolism, and oxidative phosphorylation.
  • To elucidate the influence of microenvironmental factors (T cells, stromal cells) on CLL cell metabolism.
  • To discuss the clinical potential of targeting metabolic pathways for innovative CLL therapies.

Main Methods:

  • Literature review summarizing key metabolic pathways in CLL.
  • Analysis of the impact of oncogenes (e.g., TP53, MYC) and tumor suppressors on metabolic alterations.
  • Evaluation of therapeutic agents targeting metabolic enzymes and pathways, such as statins, orlistat, and oxidative phosphorylation inhibitors.

Main Results:

  • Key metabolic processes like glycolysis, lipid metabolism, and oxidative phosphorylation are critical in CLL.
  • Metabolic reprogramming in CLL is influenced by oncogenes, tumor suppressors, and the tumor microenvironment.
  • Agents targeting metabolic enzymes (HMGCR inhibitors, lipoprotein lipase inhibitors) and oxidative phosphorylation can induce apoptosis and reduce proliferation in CLL cells.

Conclusions:

  • Metabolic reprogramming is vital for CLL initiation and progression.
  • Targeting cancer cell metabolism presents a promising therapeutic avenue for CLL.
  • Understanding CLL metabolism can lead to the development of novel targeted agents to reshape cancer cell metabolism and improve patient outcomes.